Farida Vadutovna Valeeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Farida Vadutovna Valeeva has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana A. Kiseleva
Kazan State Medical University
14 shared publications - Kamilya B. Khasanova
Kazan State Medical University
9 shared publications - Maria S. Medvedeva
Kazan State Medical University
6 shared publications - Diana R. Islamova
Kazan State Medical University
5 shared publications - Maria R. Shaidullina
Kazan State Medical University
5 shared publications - Marina Vladimirovna Shestakova
Endocrinology Research Centre, 117292 Moscow, Russia
5 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 641-646
The role of the ADRB2 gene rs1042714 polymorphism in shaping the metabolic response in patients with early disturbances of carbohydrate metabolism
Background. Individual variability in therapeutic response at the early stages of carbohydrate metabolism disorders is largely determined by genetic factors. One of the key genes involved in the regulation of energy homeostasis is ADRB2, which encodes the β₂-adrenergic receptor. The rs1042714 polymorphism may influence tissue sensitivity to insulin and the effectiveness of therapeutic interventions. However, evidence regarding its role in the dynamics of metabolic parameters in individuals with early disturbances of carbohydrate metabolism remains limited. Aim. To investigate the effect of the ADRB2 rs1042714 polymorphism on carbohydrate metabolism indicators and their changes under different therapeutic strategies in patients with early carbohydrate metabolism disorders. Materials and methods. The study included 104 participants with risk factors for type 2 diabetes mellitus, residing in the Republic of Tatarstan. Inclusion criteria comprised a history of a single episode of elevated fasting plasma glucose and one or more risk factors for type 2 diabetes mellitus. All participants underwent ADRB2 rs1042714 genotyping. Fasting glucose, glycated hemoglobin (HbA1c), insulin, C-peptide, lipid profile, as well as HOMA-IR, HOMA-β, and their modified C-peptide – adjusted versions were assessed. Patients were randomized into two therapeutic groups – diet therapy and diet therapy plus metformin – and followed for three months. Results. Carriers of the CC, CG, and GG genotypes did not differ in age, sex, or baseline metabolic parameters (p0,05). After three months, CC carriers showed a significant decrease in fasting glucose, C-peptide, and HOMA-IR(CP) values, accompanied by an increase in HOMA-β (p0,05), indicating improved insulin sensitivity. In contrast, carriers of the minor G allele demonstrated an opposite trend – higher HOMA-IR and fasting glucose. No significant differences were observed between the diet-only and diet-plus-metformin groups (p0,05). Conclusion. The rs1042714 polymorphism of the ADRB2 gene contributes to the metabolic response characteristics in patients with early carbohydrate metabolism disorders. The CC genotype is linked to a more advantageous metabolic pattern and enhanced insulin sensitivity in peripheral tissues, while the presence of the G allele appears to contribute to the progression of insulin resistance.
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 641-646
Open AccessThe role of the ADRB2 gene rs1042714 polymorphism in shaping the metabolic response in patients with early disturbances of carbohydrate metabolism
Background. Individual variability in therapeutic response at the early stages of carbohydrate metabolism disorders is largely determined by genetic factors. One of the key genes involved in the regulation of energy homeostasis is ADRB2, which encodes the β₂-adrenergic receptor. The rs1042714 polymorphism may influence tissue sensitivity to insulin and the effectiveness of therapeutic interventions. However, evidence regarding its role in the dynamics of metabolic parameters in individuals with early disturbances of carbohydrate metabolism remains limited. Aim. To investigate the effect of the ADRB2 rs1042714 polymorphism on carbohydrate metabolism indicators and their changes under different therapeutic strategies in patients with early carbohydrate metabolism disorders. Materials and methods. The study included 104 participants with risk factors for type 2 diabetes mellitus, residing in the Republic of Tatarstan. Inclusion criteria comprised a history of a single episode of elevated fasting plasma glucose and one or more risk factors for type 2 diabetes mellitus. All participants underwent ADRB2 rs1042714 genotyping. Fasting glucose, glycated hemoglobin (HbA1c), insulin, C-peptide, lipid profile, as well as HOMA-IR, HOMA-β, and their modified C-peptide – adjusted versions were assessed. Patients were randomized into two therapeutic groups – diet therapy and diet therapy plus metformin – and followed for three months. Results. Carriers of the CC, CG, and GG genotypes did not differ in age, sex, or baseline metabolic parameters (p0,05). After three months, CC carriers showed a significant decrease in fasting glucose, C-peptide, and HOMA-IR(CP) values, accompanied by an increase in HOMA-β (p0,05), indicating improved insulin sensitivity. In contrast, carriers of the minor G allele demonstrated an opposite trend – higher HOMA-IR and fasting glucose. No significant differences were observed between the diet-only and diet-plus-metformin groups (p0,05). Conclusion. The rs1042714 polymorphism of the ADRB2 gene contributes to the metabolic response characteristics in patients with early carbohydrate metabolism disorders. The CC genotype is linked to a more advantageous metabolic pattern and enhanced insulin sensitivity in peripheral tissues, while the presence of the G allele appears to contribute to the progression of insulin resistance.
- Open Access
- 13 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 40-49
Oral cavity dysbiosis and metabolic disorders in type 2 diabetes
Introduction. Type 2 diabetes mellitus (T2DM) is a chronic endocrine disorder characterized by metabolic disturbances, the etiology and pathogenesis of which have not been fully identified. Recent scientific studies demonstrate a strong association between the oral microbiome (OM) and T2DM. The OM with its extensive species diversity and metabolic profile, contributes to the onset and progression of not only local oral diseases but also systemic metabolic pathologies, including cardiovascular diseases, obesity, T2DM, and related conditions. Aim. To analyze the contribution of OM, its metabolites, and host genetic factors to the development of T2DM. Materials and methods. A systematic review of articles and original studies from PubMed, MEDLINE, and eLIBRARY databases for the period 2005–2024 was conducted. Inclusion criteria encompassed full-text peer-reviewed publications in Russian and English containing data on the microbial composition of the oral cavity in T2DM, microbial metabolome, and host genomic variations. Excluded were conference abstracts and materials unrelated to OM in T2DM. The search utilized combinations of keywords: “type 2 diabetes mellitus”, “oral microbiota”, “metagenomic/metabolomic shifts”, “prognostic biomarkers”. The initial search yielded 460 sources. After removing duplicates, applying filters, and assessing relevance, 68 sources remained for in-depth analysis (5 for the introduction, 63 for the discussion). Conclusion. The reviewed data provide a foundation for innovative diagnostic and therapeutic strategies in primary and secondary prevention of T2DM complications. Metabolomic and metagenomic approaches establish correlations between OM and T2DM onset, enable risk prediction, and facilitate the development of early intervention tools, which is critical for complication prevention.
- 13 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 40-49
Open AccessOral cavity dysbiosis and metabolic disorders in type 2 diabetes
Introduction. Type 2 diabetes mellitus (T2DM) is a chronic endocrine disorder characterized by metabolic disturbances, the etiology and pathogenesis of which have not been fully identified. Recent scientific studies demonstrate a strong association between the oral microbiome (OM) and T2DM. The OM with its extensive species diversity and metabolic profile, contributes to the onset and progression of not only local oral diseases but also systemic metabolic pathologies, including cardiovascular diseases, obesity, T2DM, and related conditions. Aim. To analyze the contribution of OM, its metabolites, and host genetic factors to the development of T2DM. Materials and methods. A systematic review of articles and original studies from PubMed, MEDLINE, and eLIBRARY databases for the period 2005–2024 was conducted. Inclusion criteria encompassed full-text peer-reviewed publications in Russian and English containing data on the microbial composition of the oral cavity in T2DM, microbial metabolome, and host genomic variations. Excluded were conference abstracts and materials unrelated to OM in T2DM. The search utilized combinations of keywords: “type 2 diabetes mellitus”, “oral microbiota”, “metagenomic/metabolomic shifts”, “prognostic biomarkers”. The initial search yielded 460 sources. After removing duplicates, applying filters, and assessing relevance, 68 sources remained for in-depth analysis (5 for the introduction, 63 for the discussion). Conclusion. The reviewed data provide a foundation for innovative diagnostic and therapeutic strategies in primary and secondary prevention of T2DM complications. Metabolomic and metagenomic approaches establish correlations between OM and T2DM onset, enable risk prediction, and facilitate the development of early intervention tools, which is critical for complication prevention.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 169-176
Modern concepts of type 2 diabetes mellitus phenotypes
In the context of the rapid increase in the prevalence of type 2 diabetes mellitus, the study of the phenotypic heterogeneity of the disease, caused by the variability of pathophysiological processes, the impact of environmental factors and individual genetic predisposition, is of particular importance. The traditional division into diabetes mellitus types 1 and 2 does not reflect the entire complexity of the pathogenesis and the diversity of clinical subtypes of type 2 diabetes mellitus. Modern studies reveal stable subgroups of patients with different clinical trajectories of disease development, which in the future will require a revision of diagnostic and therapeutic approaches. This review article analyzes studies devoted to the stratification of patients with type 2 diabetes mellitus. The key features of the most reproducible phenotypes, including severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), mild age-related diabetes (MARD), and severe autoimmune diabetes (SAID), are disclosed, their pathophysiological characteristics, clinical features, therapeutic strategies, and approaches to the prevention of diabetic complications in various subgroups are given. Independent cohort studies have confirmed stable associations of the identified phenotypes with key clinical outcomes, including the degree of glycemic control, the incidence of microvascular and macrovascular complications, and mortality rates, which can be used in the future to develop personalized patient management strategies. However, further studies are required to validate and optimize the methods for subclassifying type 2 diabetes mellitus for the justified implementation of new treatment and diagnostic algorithms in everyday clinical practice.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 169-176
Modern concepts of type 2 diabetes mellitus phenotypes
In the context of the rapid increase in the prevalence of type 2 diabetes mellitus, the study of the phenotypic heterogeneity of the disease, caused by the variability of pathophysiological processes, the impact of environmental factors and individual genetic predisposition, is of particular importance. The traditional division into diabetes mellitus types 1 and 2 does not reflect the entire complexity of the pathogenesis and the diversity of clinical subtypes of type 2 diabetes mellitus. Modern studies reveal stable subgroups of patients with different clinical trajectories of disease development, which in the future will require a revision of diagnostic and therapeutic approaches. This review article analyzes studies devoted to the stratification of patients with type 2 diabetes mellitus. The key features of the most reproducible phenotypes, including severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), mild age-related diabetes (MARD), and severe autoimmune diabetes (SAID), are disclosed, their pathophysiological characteristics, clinical features, therapeutic strategies, and approaches to the prevention of diabetic complications in various subgroups are given. Independent cohort studies have confirmed stable associations of the identified phenotypes with key clinical outcomes, including the degree of glycemic control, the incidence of microvascular and macrovascular complications, and mortality rates, which can be used in the future to develop personalized patient management strategies. However, further studies are required to validate and optimize the methods for subclassifying type 2 diabetes mellitus for the justified implementation of new treatment and diagnostic algorithms in everyday clinical practice.
- Open Access
- 10 February 2025
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 16 (1) , 39-45
Association of rs622342 SLC22A1 with the short-term changes of lipid and carbohydrate metabolism indicators in different variants of early carbohydrate metabolism disorders management in women
Objective: to analyze the association of rs622342 SLC22A1 with the short-term changes in fat and carbohydrate metabolism parameters in various types of early carbohydrate metabolism disorders therapy. Materials and methods: the results of management of 89 patients with excess body weight and risk factors for type 2 diabetes mellitus development were analyzed. For 3 months, 53 patients followed diet therapy, 36 patients took metformin in addition to the diet. All of the patients were genotyped for rs622342 SLC22A1. Also initially and 3 months after the beginning of therapy fasting plasma glucose, glycosylated hemoglobin, total cholesterol, low-density and high-density lipoproteins, tryglicerides were measured. Statistical processing was carried out using parametric and non-parametric criteria. Results: 3 months after the start of diet therapy, homozygous СС-carriers of the rs622342 SLC22A1 showed a significant decrease in total cholesterol and triglycerides compared with A-allele carriers. These changes were not observed when metformin was added to diet therapy. There were no significant differences in changes of fasting plasma glucose and glycated hemoglobin levels in groups with different management. Conclusions: carriers of CC rs622342 SLC22A1 are characterized with the significant decrease in total cholesterol and triglycerides levels compared to the A-allele carriers after 3 months of standard diet therapy; when metformin is added to the treatment regimen, these changes are not observed.
- 10 February 2025
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 16 (1) , 39-45
Open AccessAssociation of rs622342 SLC22A1 with the short-term changes of lipid and carbohydrate metabolism indicators in different variants of early carbohydrate metabolism disorders management in women
Objective: to analyze the association of rs622342 SLC22A1 with the short-term changes in fat and carbohydrate metabolism parameters in various types of early carbohydrate metabolism disorders therapy. Materials and methods: the results of management of 89 patients with excess body weight and risk factors for type 2 diabetes mellitus development were analyzed. For 3 months, 53 patients followed diet therapy, 36 patients took metformin in addition to the diet. All of the patients were genotyped for rs622342 SLC22A1. Also initially and 3 months after the beginning of therapy fasting plasma glucose, glycosylated hemoglobin, total cholesterol, low-density and high-density lipoproteins, tryglicerides were measured. Statistical processing was carried out using parametric and non-parametric criteria. Results: 3 months after the start of diet therapy, homozygous СС-carriers of the rs622342 SLC22A1 showed a significant decrease in total cholesterol and triglycerides compared with A-allele carriers. These changes were not observed when metformin was added to diet therapy. There were no significant differences in changes of fasting plasma glucose and glycated hemoglobin levels in groups with different management. Conclusions: carriers of CC rs622342 SLC22A1 are characterized with the significant decrease in total cholesterol and triglycerides levels compared to the A-allele carriers after 3 months of standard diet therapy; when metformin is added to the treatment regimen, these changes are not observed.
- Open Access
- 15 September 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (4) , 65-74
Multiplex analysis of post-Covid cardiorenal complications in patients with type 1 and type 2 diabetes mellitus according to the mobile diagnostic and treatment center (Diamobil)
BACKGROUND: Patients with diabetes mellitus (DM) are at risk for a higher incidence and severity of COVID-19, as well as its adverse outcomes, including post-Covid syndrome.AIM: to assess the incidence of cardiorenal complications in patients with type 1 and type 2 diabetes (T1DM/T2DM) who have had COVID-19, and to analyze the structure and severity of disorders according to examination data at the Diamobil mobile medical diagnostic and treatment center.MATERIALS AND METHODS: a cohort of T1DM and T2DM patients examined in Diamobil (n=318), with a confirmed anamnesis of COVID-19 (n=236). The time interval between COVID-19 and the visit to Diamobil was 8.7/8.2 months for T1DM/T2DM. The parameters of the last visit before COVID-19 recorded in the Federal Register of Diabetes (FRD) were used as initial data.RESULTS: Clinical characteristics of patients with T1DM/T2DM: age — 49.2/64.5 years, duration of DM — 22/11 years, proportion of women — 64/73%, respectively. After analysis the data from visits before and after COVID-19 there weren’t statistically significant differences in HbA1c levels for both types of DM (before 9.0/8.3%; after 8.4/8.2%, respectively), there was the intensification of glucose lowering therapy (the proportion of patients with T2DM on 2 and 3 component therapy increased by 4.3% and 1.6%, the proportion of patients on insulin therapy by 16%). After COVID-19, there was a statistically significant decrease in glomerular filtration rate (GFR) in T1DM from 88.1 to 62 ml/min/1.73 m2; with T2DM from 74.7 to 54.1 ml/min/1.73 m2. When assessing acute diabetic complications, there was an increase in the frequency of coma in T1DM by 1.5 times, severe hypoglycemia in T1DM by 3 times, and in T2DM by 1.7 times. Analysis of the frequency of cardiorenal complications before and after COVID-19 showed a total increase of 8.5% in T1DM, by 13.2% in T2DM, of which myocardial infarction, ischemic heart disease, and CHF increased in T1DM in the range from 1.5 to 5 times, with T2DM by 1.3 times, the frequency of CKD with T1DM by 1.5 times, with T2DM by 5.6 times.CONCLUSION: There was a decline of kidney filtration function (decrease in GFR) and an increase in the frequency of cardiovascular complications in both types of diabetes in post-Covid period while patients achieved a stable HbA1c levels by intensifying therapy during the COVID-19 infection. This fact reflects combined damage to the kidney and cardiovascular system as a part of the post-Covid syndrome and determines a key set of measures for the development of preventive strategies.
- 15 September 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (4) , 65-74
Open AccessMultiplex analysis of post-Covid cardiorenal complications in patients with type 1 and type 2 diabetes mellitus according to the mobile diagnostic and treatment center (Diamobil)
BACKGROUND: Patients with diabetes mellitus (DM) are at risk for a higher incidence and severity of COVID-19, as well as its adverse outcomes, including post-Covid syndrome.AIM: to assess the incidence of cardiorenal complications in patients with type 1 and type 2 diabetes (T1DM/T2DM) who have had COVID-19, and to analyze the structure and severity of disorders according to examination data at the Diamobil mobile medical diagnostic and treatment center.MATERIALS AND METHODS: a cohort of T1DM and T2DM patients examined in Diamobil (n=318), with a confirmed anamnesis of COVID-19 (n=236). The time interval between COVID-19 and the visit to Diamobil was 8.7/8.2 months for T1DM/T2DM. The parameters of the last visit before COVID-19 recorded in the Federal Register of Diabetes (FRD) were used as initial data.RESULTS: Clinical characteristics of patients with T1DM/T2DM: age — 49.2/64.5 years, duration of DM — 22/11 years, proportion of women — 64/73%, respectively. After analysis the data from visits before and after COVID-19 there weren’t statistically significant differences in HbA1c levels for both types of DM (before 9.0/8.3%; after 8.4/8.2%, respectively), there was the intensification of glucose lowering therapy (the proportion of patients with T2DM on 2 and 3 component therapy increased by 4.3% and 1.6%, the proportion of patients on insulin therapy by 16%). After COVID-19, there was a statistically significant decrease in glomerular filtration rate (GFR) in T1DM from 88.1 to 62 ml/min/1.73 m2; with T2DM from 74.7 to 54.1 ml/min/1.73 m2. When assessing acute diabetic complications, there was an increase in the frequency of coma in T1DM by 1.5 times, severe hypoglycemia in T1DM by 3 times, and in T2DM by 1.7 times. Analysis of the frequency of cardiorenal complications before and after COVID-19 showed a total increase of 8.5% in T1DM, by 13.2% in T2DM, of which myocardial infarction, ischemic heart disease, and CHF increased in T1DM in the range from 1.5 to 5 times, with T2DM by 1.3 times, the frequency of CKD with T1DM by 1.5 times, with T2DM by 5.6 times.CONCLUSION: There was a decline of kidney filtration function (decrease in GFR) and an increase in the frequency of cardiovascular complications in both types of diabetes in post-Covid period while patients achieved a stable HbA1c levels by intensifying therapy during the COVID-19 infection. This fact reflects combined damage to the kidney and cardiovascular system as a part of the post-Covid syndrome and determines a key set of measures for the development of preventive strategies.
- Open Access
- 20 May 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (4) , 219-224
The role of genes and myokines of developing sarcopenia: A review
Sarcopenia is associated with progressive generalized skeletal muscle weakness, persistent decline in muscle strength, function, and quality of life in the elderly population. The presence of sarcopenia worsens the prognosis of older patients. In this regard, the study of the etiology and pathogenesis of sarcopenia, the identification of early markers for the diagnosis of this disease are relevant areas today. Myokines are secreted by skeletal muscle and play a important role in the regulation of muscle mass and function, metabolic homeostasis. Myokine synthesis disruption may contribute to the development of sarcopenia. In addition, we can see the polymorphism association of various genes with the development of the disease. This review brings together current knowledge about myokines and genetic factors as potential biomarkers for the early diagnosis of sarcopenia.
- 20 May 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (4) , 219-224
Open AccessThe role of genes and myokines of developing sarcopenia: A review
Sarcopenia is associated with progressive generalized skeletal muscle weakness, persistent decline in muscle strength, function, and quality of life in the elderly population. The presence of sarcopenia worsens the prognosis of older patients. In this regard, the study of the etiology and pathogenesis of sarcopenia, the identification of early markers for the diagnosis of this disease are relevant areas today. Myokines are secreted by skeletal muscle and play a important role in the regulation of muscle mass and function, metabolic homeostasis. Myokine synthesis disruption may contribute to the development of sarcopenia. In addition, we can see the polymorphism association of various genes with the development of the disease. This review brings together current knowledge about myokines and genetic factors as potential biomarkers for the early diagnosis of sarcopenia.
- Open Access
- 20 May 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (4) , 232-237
Comparative analysis of the association of polymorphism rs9939609 of the FTO gene in patients with type 2 diabetes mellitus in the Tatar and Yakut populations
Background. One of the most important gene polymorphisms that may be responsible for the development of insulin resistance is the rs9939609 of the FTO gene. Aim. To investigate the association of the rs9939609 polymorphism of the FTO gene in patients with type 2 diabetes (T2D) in the Yakut and Tatar populations. Materials and methods. The study involved patients with T2D from the population of the Yakut nationality of the Republic of Sakha (Yakutia), Yakutsk (n=132) and the Tatar population – residents of the Republic of Tatarstan (n=134). Molecular genetic analysis was carried out on in the central research laboratory of the Department of molecular genetics (Kazan State Medical University) and in the laboratory of hereditary pathology of the Department of Molecular Genetics (Yakut Science Center of Complex Medical Problems). Statistical data processing was carried out using GraphPad InStat, Microsoft Excel 2007 programs. Results. The frequency of the AA genotype of the rs9939609 polymorphism of the FTO gene in the group of T2D in the Tatar population differed from the own control sample: 30.1% vs 14.1%; p=0.00000006, as well as from the European control group from the 1000GENOME database: 30.1% vs 19.9%; p=0.0006. The frequency of the risk allele in T2D group in the Yakut population was statistically significantly higher than in the East Asian control group from the 1000GENOME database (27.7% vs 16.9%; p=0.00007), in the own healthy control group no significant differences were found. Conclusion. The more the Asian component in the genome of the population, the less it is predisposed to obesity and T2D. The rs9939609 polymorphism of the FTO gene is associated with the risk of T2D in the Tatar population; no association in the Yakut population was found.
- 20 May 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (4) , 232-237
Open AccessComparative analysis of the association of polymorphism rs9939609 of the FTO gene in patients with type 2 diabetes mellitus in the Tatar and Yakut populations
Background. One of the most important gene polymorphisms that may be responsible for the development of insulin resistance is the rs9939609 of the FTO gene. Aim. To investigate the association of the rs9939609 polymorphism of the FTO gene in patients with type 2 diabetes (T2D) in the Yakut and Tatar populations. Materials and methods. The study involved patients with T2D from the population of the Yakut nationality of the Republic of Sakha (Yakutia), Yakutsk (n=132) and the Tatar population – residents of the Republic of Tatarstan (n=134). Molecular genetic analysis was carried out on in the central research laboratory of the Department of molecular genetics (Kazan State Medical University) and in the laboratory of hereditary pathology of the Department of Molecular Genetics (Yakut Science Center of Complex Medical Problems). Statistical data processing was carried out using GraphPad InStat, Microsoft Excel 2007 programs. Results. The frequency of the AA genotype of the rs9939609 polymorphism of the FTO gene in the group of T2D in the Tatar population differed from the own control sample: 30.1% vs 14.1%; p=0.00000006, as well as from the European control group from the 1000GENOME database: 30.1% vs 19.9%; p=0.0006. The frequency of the risk allele in T2D group in the Yakut population was statistically significantly higher than in the East Asian control group from the 1000GENOME database (27.7% vs 16.9%; p=0.00007), in the own healthy control group no significant differences were found. Conclusion. The more the Asian component in the genome of the population, the less it is predisposed to obesity and T2D. The rs9939609 polymorphism of the FTO gene is associated with the risk of T2D in the Tatar population; no association in the Yakut population was found.
- Open Access
- 20 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 240-249
Association between gut microbiota and thyroid dysfunction
The article is devoted to modern researches about the potential role of gut microbiota in the development of thyroid pathology. Gut microbiota plays a major role both in the formation and maintenance of human health and in the pathogenesis of a wide range of diseases. There is evidence of the relationship between the gut microbiota and the immune system, the risk of developing several malignant and autoimmune diseases. The article discusses the functions of the gut microbiota and the factors that determine its composition. Studies have shown a connection between the gut microbiota and the thyroid gland, which formed the basis for the formation of the theory of the gut-thyroid axis. It has been shown that the gut microbiota takes part in the metabolism of thyroid hormones and ensures their enterohepatic circulation. It is assumed that one of the links between the thyroid gland and gastrointestinal microorganisms is the immune system. The results of studies examining the taxonomic composition of the gut microbiota in patients with autoimmune thyroiditis and Graves’ disease are presented. It is hypothesized that the composition of the gut microbiota may influence the requirement for levothyroxine, especially in patients with subclinical hypothyroidism. On the other hand, levothyroxine, to a lesser extent, directly hypothyroidism as a result of autoimmune thyroiditis are associated with bacterial overgrowth syndrome despite the achievement of euthyroidism, and may affect the composition of the microbiota. Even though autoimmune thyroid diseases are quite common in the general population, little work has been done on this issue. More reliable basic and clinical researches are needed to identify specific relationships and mechanisms of development of thyroid pathology depending on changes in the composition of the gut microbiota, as well as to assess the potential for therapeutic use.
- 20 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 240-249
Open AccessAssociation between gut microbiota and thyroid dysfunction
The article is devoted to modern researches about the potential role of gut microbiota in the development of thyroid pathology. Gut microbiota plays a major role both in the formation and maintenance of human health and in the pathogenesis of a wide range of diseases. There is evidence of the relationship between the gut microbiota and the immune system, the risk of developing several malignant and autoimmune diseases. The article discusses the functions of the gut microbiota and the factors that determine its composition. Studies have shown a connection between the gut microbiota and the thyroid gland, which formed the basis for the formation of the theory of the gut-thyroid axis. It has been shown that the gut microbiota takes part in the metabolism of thyroid hormones and ensures their enterohepatic circulation. It is assumed that one of the links between the thyroid gland and gastrointestinal microorganisms is the immune system. The results of studies examining the taxonomic composition of the gut microbiota in patients with autoimmune thyroiditis and Graves’ disease are presented. It is hypothesized that the composition of the gut microbiota may influence the requirement for levothyroxine, especially in patients with subclinical hypothyroidism. On the other hand, levothyroxine, to a lesser extent, directly hypothyroidism as a result of autoimmune thyroiditis are associated with bacterial overgrowth syndrome despite the achievement of euthyroidism, and may affect the composition of the microbiota. Even though autoimmune thyroid diseases are quite common in the general population, little work has been done on this issue. More reliable basic and clinical researches are needed to identify specific relationships and mechanisms of development of thyroid pathology depending on changes in the composition of the gut microbiota, as well as to assess the potential for therapeutic use.
- Open Access
- 18 December 2023
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 40 (5) , 73-79
Personalized therapy of type 2 diabetes mellitus
Currently, the contribution of genetic factors to the development of type 2 diabetes is becoming more obvious. Despite the available nine classes of hypoglycemic drugs, only 35–40 % of patients achieve an adequate glycemic control. One the reasons may be the genetic heterogeneity of diabetes mellitus. An increasing number of studies indicates that an individual set of gene polymorphisms can determine the therapeutic response to a particular drug and cause the development of undesirable effects. The article presents an overview of a new direction in the diagnosis and treatment of diabetes mellitus – personalized medicine. The pathogenetic mechanisms of the development of the disease, its heterogeneity and the difficulties of choosing the most effective hypoglycemic therapy are described. Data on the pharmacogenetic features of metformin are presented.
- 18 December 2023
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 40 (5) , 73-79
Open AccessPersonalized therapy of type 2 diabetes mellitus
Currently, the contribution of genetic factors to the development of type 2 diabetes is becoming more obvious. Despite the available nine classes of hypoglycemic drugs, only 35–40 % of patients achieve an adequate glycemic control. One the reasons may be the genetic heterogeneity of diabetes mellitus. An increasing number of studies indicates that an individual set of gene polymorphisms can determine the therapeutic response to a particular drug and cause the development of undesirable effects. The article presents an overview of a new direction in the diagnosis and treatment of diabetes mellitus – personalized medicine. The pathogenetic mechanisms of the development of the disease, its heterogeneity and the difficulties of choosing the most effective hypoglycemic therapy are described. Data on the pharmacogenetic features of metformin are presented.
- Open Access
- 28 August 2023
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 14 (3) , 37-40
Clinical Case of Mccune-Albright-Braitsev Syndrome (MAS)
The presented clinical case describes orphan disease known as MAS with manifested symptoms of precocious puberty, recurrent ovarian cysts, fibrous dysplasia, café-au-lait skin pigmentation and abnormal cardiac conduction. The pathogenesis is based on the GNAS gene mutation that cause hyperactivation of glycoprotein hormone receptors and hypersecretion. There are genetic tests that confirm the diagnosis, however, given the high percentage of false negative results, in most cases the disease is diagnosed based on a combination of clinical and laboratory-instrumental data. Given the high clinical variability and absence of management algorithms for patient with this syndrome, the article pinpoints the necessity of thorough examination of patients to select further management tactics. Multidisciplinary approach and collegiate case management will improve diagnosis of the disease and prevent the development of severe complications.
- 28 August 2023
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 14 (3) , 37-40
Open AccessClinical Case of Mccune-Albright-Braitsev Syndrome (MAS)
The presented clinical case describes orphan disease known as MAS with manifested symptoms of precocious puberty, recurrent ovarian cysts, fibrous dysplasia, café-au-lait skin pigmentation and abnormal cardiac conduction. The pathogenesis is based on the GNAS gene mutation that cause hyperactivation of glycoprotein hormone receptors and hypersecretion. There are genetic tests that confirm the diagnosis, however, given the high percentage of false negative results, in most cases the disease is diagnosed based on a combination of clinical and laboratory-instrumental data. Given the high clinical variability and absence of management algorithms for patient with this syndrome, the article pinpoints the necessity of thorough examination of patients to select further management tactics. Multidisciplinary approach and collegiate case management will improve diagnosis of the disease and prevent the development of severe complications.